BIOVERATIV INC. is an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.[1] Bioverativ competes with Baxalta (acquired by Shire Plc in 2016[2]), Pfizer and Novo Nordisk.[3] The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.
